Micafungin in combination with voriconazole in Aspergillus species: A pharmacodynamic approach for detection of combined antifungal activity in vitro

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 5, 2005, Pages 887-892

  Lewis, Russell E ^a,b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aspergillosis; Echinocandins; Triazoles

Indexed keywords

MICAFUNGIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; COLORIMETRY; CONCENTRATION RESPONSE; DILUTION; DRUG POTENTIATION; FLUORESCENCE; FLUORESCENCE MICROSCOPY; FUNGUS GROWTH; FUNGUS HYPHAE; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SENSITIVITY ANALYSIS; SPECIES DIFFERENCE;

ANTIFUNGAL AGENTS; ASPERGILLUS; DRUG COMBINATIONS; FLUORESCENCE; FUNGAL PROTEINS; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, FLUORESCENCE; PEPTIDES, CYCLIC; PYRIMIDINES; STAINING AND LABELING; TRIAZOLES;

EID: 27744526752     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki343     Document Type: Article

References (14)

1. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-7.
2. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med 2002; 347: 408-15.
3. Kontoyiannis D, Lewis R. Combination chemotherapy for invasive fungal infections: What laboratory and clinical studies tell us so far. Drug Resist Updat 2003; 6: 257-69.
4. Kirkpatrick W, Perea S, Coco BJ et al. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564-8.
5. Petraitis V, Petraitiene R, Sarafandi A et al. Combination therapy in treatment of experimental pulmonary aspergillosis: Synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: 1834-43.
6. Marr K, Boeckh M, Carter R et al. Combination therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
7. Odds F. Synergy, antagonism and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
8. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard M38-A. NCCLS, Wayne, PA, USA, 2002.
9. Kurtz M, Heath I, Marrinan J et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480-9.
10. Meletiadis J, Mouton J, Meis J et al. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001; 39: 3402-8.
11. Lewis R, Wiederhold N, Klepser M. In vitro pharmacodynamics of amphotericin B, voriconazole, and itraconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob Agents Chemother 2005; 49: 945-51.
12. Bowman J, Hicks P, Kurtz M et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001-12.
13. Eliopoulos G, Moellering R. Antimicrobial combinations. In: Lorian V, ed. Antibiotics and Laboratory Medicine, 4th edn. Baltimore, MD: Williams and Wilkins.
14. Meletiadis J, Meis J, Mouton J et al. Methodological issues related to antifungal drug interaction modeling for filamentous fungi. Rev Clin Microbiol 2002; 13: 101-17.